Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00744692 · ClinicalTrials.gov registry record · Phase 1
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
A Phase 1 study of Thalassemia and Hemoglobinopathies, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT00744692 is a Phase 1 study of Thalassemia and Hemoglobinopathies that has completed, run by Duke University. The registered enrollment target is 22 participants, below the 89-participant average among 19 other Thalassemia trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00744692, a Phase 1 study of Thalassemia and Hemoglobinopathies, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective is to determine the feasibility of attaining acceptable rates of donor cell engraftment (\>25% donor chimerism at 180 days) following reduced intensity conditioning (RIC) regimens in pediatric patients \< 21 years receiving cord blood transplantation for non-malignant disorders.
Conditions Studied
Interventions
- DRUG Reduced Intensity Conditioning
- BIOLOGICAL Unrelated Umbilical Cord Blood Transplant
Study Locations (1)
North Carolina
- Duke University Medical Center Pediatric Blood and Marrow Transplant Program - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2008-10 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00744692
The ClinicalTrials.gov registry entry for NCT00744692 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 89-participant average among 19 other Thalassemia trials with a reported enrollment target (75% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Thalassemia appearing as the primary indexed condition, and to 2 interventions - of which Reduced Intensity Conditioning is the first listed.
NCT00744692 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT00744692 about?
NCT00744692 is a clinical study titled "Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders". The primary objective is to determine the feasibility of attaining acceptable rates of donor cell engraftment (\>25% donor chimerism at 180 days) following reduced intensity conditioning (RIC) regimens in pediatric patients \< 21 years receiving cord blood transplantation for non-malignant disorders...
What is the current status of trial NCT00744692?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2008-10. Estimated completion is 2014-04.
What conditions does trial NCT00744692 study?
This clinical trial studies the following conditions: Thalassemia, Hemoglobinopathies, Immunodeficiencies, Inborn Errors of Metabolism, Non-malignant Disorders.
What interventions are being tested in trial NCT00744692?
The interventions under investigation include: Reduced Intensity Conditioning (DRUG), Unrelated Umbilical Cord Blood Transplant (BIOLOGICAL).
Who is sponsoring clinical trial NCT00744692?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00744692 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thalassemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Blood Stem Cell Transplant for Sickle Cell Disease
ACTIVE NOT RECRUITING · Phase 1
-
Combination Iron Chelation Therapy
COMPLETED · Phase 1
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
RECRUITING · Phase 3
-
Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling
RECRUITING · Early Phase 1
-
Effect of Exercise on Body Composition and Bone Health in Patients With Thalassemia
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.